# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and lowers the price target...
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate ...
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.
HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $14 price ta...